Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
1.975
+0.025 (1.28%)
Apr 15, 2026, 1:02 PM EDT - Market open
Company Description
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.
The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.
The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.
Enveric Biosciences, Inc.
| Country | United States |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Joseph Tucker |
Contact Details
Address: 245 First Street, Riverview II Cambridge, Massachusetts 02142 United States | |
| Website | enveric.com |
Stock Details
| Ticker Symbol | ENVB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 890821 |
| CUSIP Number | 29405E505 |
| ISIN Number | US29405E5050 |
| Employer ID | 95-4484725 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Edward Tucker Ph.D. | Chief Executive Officer and Director |
| Kevin M. Coveney CPA | Chief Financial Officer |
| Dr. Peter J. Facchini Ph.D. | Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2026 | ARS | Filing |
| Apr 14, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 14, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 27, 2026 | 10-K | Annual Report |
| Mar 27, 2026 | 8-K | Current Report |
| Feb 18, 2026 | 424B3 | Prospectus |
| Feb 17, 2026 | EFFECT | Notice of Effectiveness |
| Feb 11, 2026 | D | Notice of Exempt Offering of Securities |
| Feb 10, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |